We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO - Free Report) , a global healthcare company, is a leader in the worldwide diabetes market. The company operates through two segments: Diabetes and obesity care and Biopharmaceuticals.
Analysts have recently taken a bullish stance on the company’s earnings outlook, helping land the stock into the highly-coveted Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
Aside from the improved earnings outlook, let’s look at several other aspects of NVO shares.
Current Standing
For those seeking dividends, Novo Nordisk has that covered; NVO shares currently yield 1.1% annually, with the company’s payout sitting at a sustainable 45% of earnings.
While the current yield is below the Zacks Medical sector average, the company’s 9.4% five-year annualized dividend growth rate helps bridge the gap.
Image Source: Zacks Investment Research
Shares may not entice value-focused investors, with the current 31.1X forward earnings multiple sitting on the higher end of the spectrum and well above the 24.5X five-year median. The stock carries a Style Score of “D” for Value.
Image Source: Zacks Investment Research
Still, investors have had little issue forking up the premium for NVO shares given the company’s growth profile, with earnings forecasted to climb nearly 50% in its current fiscal year (FY23) and an additional 17% in FY24.
The stock carries a Style Score of “A” for Growth.
Image Source: Zacks Investment Research
Keep an eye out for the company’s upcoming quarterly report expected on August 2nd; the Zacks Consensus EPS Estimate of $1.29 indicates a sizable 53% uptick in earnings year-over-year. In addition, it’s worth noting that the quarterly EPS estimate has been revised nearly 12% higher just since March.
Further, the company is forecasted to post $8.3 billion in quarterly revenue, reflecting more than 40% improvement from the year-ago period. The quarterly sales estimate has been revised nearly 15% higher since March.
Bottom Line
Investors can implement a stellar strategy to find expected winners by taking advantage of the Zacks Rank – one of the most powerful market tools that provides a massive edge.
Additionally, the top 5% of all stocks receive the highly coveted Zacks Rank #1 (Strong Buy). These stocks should outperform the market more than any other rank.
Novo Nordisk (NVO - Free Report) would be an excellent stock for investors to keep on their watchlists, as displayed by its Zack Rank #1 (Strong Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bull of the Day: Novo Nordisk (NVO)
Novo Nordisk (NVO - Free Report) , a global healthcare company, is a leader in the worldwide diabetes market. The company operates through two segments: Diabetes and obesity care and Biopharmaceuticals.
Analysts have recently taken a bullish stance on the company’s earnings outlook, helping land the stock into the highly-coveted Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
Aside from the improved earnings outlook, let’s look at several other aspects of NVO shares.
Current Standing
For those seeking dividends, Novo Nordisk has that covered; NVO shares currently yield 1.1% annually, with the company’s payout sitting at a sustainable 45% of earnings.
While the current yield is below the Zacks Medical sector average, the company’s 9.4% five-year annualized dividend growth rate helps bridge the gap.
Image Source: Zacks Investment Research
Shares may not entice value-focused investors, with the current 31.1X forward earnings multiple sitting on the higher end of the spectrum and well above the 24.5X five-year median. The stock carries a Style Score of “D” for Value.
Image Source: Zacks Investment Research
Still, investors have had little issue forking up the premium for NVO shares given the company’s growth profile, with earnings forecasted to climb nearly 50% in its current fiscal year (FY23) and an additional 17% in FY24.
The stock carries a Style Score of “A” for Growth.
Image Source: Zacks Investment Research
Keep an eye out for the company’s upcoming quarterly report expected on August 2nd; the Zacks Consensus EPS Estimate of $1.29 indicates a sizable 53% uptick in earnings year-over-year. In addition, it’s worth noting that the quarterly EPS estimate has been revised nearly 12% higher just since March.
Further, the company is forecasted to post $8.3 billion in quarterly revenue, reflecting more than 40% improvement from the year-ago period. The quarterly sales estimate has been revised nearly 15% higher since March.
Bottom Line
Investors can implement a stellar strategy to find expected winners by taking advantage of the Zacks Rank – one of the most powerful market tools that provides a massive edge.
Additionally, the top 5% of all stocks receive the highly coveted Zacks Rank #1 (Strong Buy). These stocks should outperform the market more than any other rank.
Novo Nordisk (NVO - Free Report) would be an excellent stock for investors to keep on their watchlists, as displayed by its Zack Rank #1 (Strong Buy).